Davison Emma K, Petrone David A, Meanwell Michael, Nodwell Matthew B, Silverman Steven M, Campeau Louis-Charles, Britton Robert
Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
Department of Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA.
Nat Protoc. 2022 Sep;17(9):2008-2024. doi: 10.1038/s41596-022-00705-7. Epub 2022 Jul 4.
Nucleoside analogs are valuable commodities in the development of antisense oligonucleotides or as stand-alone antiviral and anticancer therapies. Syntheses of nucleoside analogs are typically challenged by a reliance on chiral pool starting materials and inefficient synthetic routes that are not readily amenable to diversification. The novel methodology described in this protocol addresses several longstanding challenges in nucleoside analog synthesis by enabling flexible and selective access to nucleoside analogs possessing variable nucleobase substitution, D- or L-configuration, selective protection of C3'/C5' alcohols and C2' or C4' derivatizations. This protocol provides direct access to C3'/C5' protected nucleoside analogs in three steps from simple, achiral starting materials and is described on both research (2.8 g) and process (30 g) scales for the synthesis of C3'/C5'-acetonide protected uridine. Using this protocol, proline catalyzes the fluorination of simple heteroaryl-substituted aldehyde starting materials, which are then directly engaged in a one-pot enantioselective aldol reaction with a dioxanone. Reduction, followed by intramolecular annulative fluoride displacement, forges the nucleoside analog. The three-step parent protocol can be completed in ~5 d by using simple mix-and-stir reaction procedures and standard column chromatographic purification techniques.
核苷类似物在反义寡核苷酸的开发中或作为独立的抗病毒和抗癌疗法都是有价值的商品。核苷类似物的合成通常面临挑战,依赖于手性池起始原料以及低效的合成路线,这些路线不易于多样化。本方案中描述的新方法通过灵活且选择性地获得具有可变核碱基取代、D-或L-构型、C3'/C5'醇的选择性保护以及C2'或C4'衍生化的核苷类似物,解决了核苷类似物合成中几个长期存在的挑战。该方案从简单的非手性起始原料分三步直接获得C3'/C5'保护的核苷类似物,并针对C3'/C5'-丙酮叉保护的尿苷的合成,在研究规模(2.8 g)和工艺规模(30 g)上进行了描述。使用该方案,脯氨酸催化简单的杂芳基取代醛起始原料的氟化反应,然后这些原料直接与二氧杂环己酮进行一锅法对映选择性羟醛反应。还原反应,随后进行分子内环化氟取代反应,生成核苷类似物。通过使用简单的混合搅拌反应程序和标准柱色谱纯化技术,三步母体方案大约可以在5天内完成。